Clincosm LogoSign in Get a demo

High-grade B-cell Lymphoma

Showing 1 - 25 of 30
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma Trial in China (Relmacabtagene

Not yet recruiting
  • Lymphoma, Large B-Cell, Diffuse
  • +3 more
  • Relmacabtagene Autoleucel
  • +2 more
  • Guangzhou, Guangdong, China
  • +12 more
Oct 24, 2023

Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

Not yet recruiting
  • Non-hodgkin Lymphoma
  • +9 more
  • CD79b-19 CAR T cells
  • +2 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Sep 6, 2023

Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma Trial in Boston (Adaptive Bridging Radiation Therapy (ABRT))

Not yet recruiting
  • Lymphoma, B-Cell
  • +7 more
  • Adaptive Bridging Radiation Therapy (ABRT)
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 16, 2023

Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Not yet recruiting
  • Lymphoma, B-Cell
  • +6 more
  • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
  • Guayaquil, Guayas, Ecuador
    Instituto Oncológico Nacional Dr. Juan Tanca Marengo
Apr 27, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

NHL, Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis, Saint Louis (FT596, Rituximab)

Suspended
  • NHL
  • +3 more
  • Minneapolis, Minnesota
  • +1 more
Jan 31, 2023

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Study of CAR-T Therapy in Older Patients

Recruiting
  • Lymphoma
  • +5 more
  • Activities of Daily Living/ADLs
  • +10 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma Trial in Saint Louis (Mosunetuzumab)

Recruiting
  • B Cell Lymphoma
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 3, 2023

DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • High-grade B-cell Lymphoma
  • Loncastuximab Tesirine
  • (no location specified)
Dec 13, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma Trial in Japan (epcoritamab

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • epcoritamab (monotherapy)
  • +5 more
  • Chuo Ku, Japan
  • +19 more
Nov 22, 2022

B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Korea, Republic of, United

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
  • +8 more
Oct 17, 2022

Mature B-Cell Tumor, Non Hodgkin Lymphoma, DLBCL Trial (SGR-1505)

Not yet recruiting
  • Mature B-Cell Neoplasm
  • +25 more
  • (no location specified)
Sep 14, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed B-Cell Lymphoma Trial in Saint Louis (Mosunetuzumab,

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +3 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 14, 2022

DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
Jul 1, 2022

Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (GEN3009, Epcoritamab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • +7 more
  • GEN3009
  • Epcoritamab
  • Tucson, Arizona
  • +31 more
Jul 1, 2022

B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Taipei (RPM

Terminated
  • B-cell Acute Lymphoblastic Leukemia
  • +7 more
  • RPM CD19-mbIL15-CAR-T cells
  • Taipei, Taiwan
    National Taiwan University Hospital
May 11, 2022

Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (Toripalimab,

Recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • Toripalimab, Rituximab
  • R-CHOP Protocol
  • Guangzhou, Guangdong, China
    Department of hematology department, Nanfang hospital
Apr 6, 2022

Non Hodgkin Lymphoma, Lymphoma, B-Cell, High-grade B-cell Lymphoma Trial in Belgium, Netherlands (DA-EPOCH-R followed by

Active, not recruiting
  • Non Hodgkin Lymphoma
  • +4 more
  • DA-EPOCH-R followed by Nivolumab
  • Antwerpen, Belgium
  • +23 more
Mar 23, 2022

High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

Not yet recruiting
  • High-grade B-cell Lymphoma
  • +8 more
  • Sepantronium Bromide
  • Busan, Korea, Republic of
  • +5 more
Feb 27, 2022

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

Active, not recruiting
  • Classical Hodgkin Lymphoma
  • +12 more
    • Bedford, Bedfordshire, United Kingdom
    • +8 more
    Feb 22, 2022

    Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma Trial in China (Rituximab, Etoposide,

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +2 more
    • Changsha, Hunan, China
    • +5 more
    Jan 24, 2022

    Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma Trial in Worldwide (RO6870810, Venetoclax, Rituximab)

    Completed
    • Diffuse Large B-cell Lymphoma
    • High-Grade B-cell Lymphoma
    • Duarte, California
    • +8 more
    Jan 21, 2022

    Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) Trial in Seoul (CRC01,

    Recruiting
    • Relapsed Large B-cell Lymphoma
    • +5 more
    • CRC01
    • +2 more
    • Seoul, Korea, Republic of
      Samsung Medical Center
    Apr 29, 2021

    Non-GCB/ABC DLBCL, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb Trial in Guangzhou (PD-1 Antibody, Lenalidomide)

    Recruiting
    • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
    • +5 more
    • Guangzhou, Guangdong, China
      Department of Medical Oncology, Sun Yat-sen University Cancer Ce
    Mar 12, 2021